Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune protein G-CSF put to the test for unexplained recurrent miscarriage

NCT ID NCT07724405

Recruiting now Disease control Sponsor: Fakih IVF Fertility Center Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a daily injection of granulocyte colony-stimulating factor (G-CSF), a protein that helps regulate the immune system, can improve pregnancy success in women with unexplained recurrent miscarriage after IVF. Only women whose embryos have been genetically confirmed as normal are included, so any pregnancy loss is likely due to the mother's immune response rather than embryo quality. Participants receive either G-CSF or a placebo from embryo transfer until 12 weeks of pregnancy, and the study tracks clinical pregnancy rates at 16 weeks and live birth rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a naturally occurring immune-modulating protein called granulocyte colony-stimulating factor (G-CSF), given as a daily injection
What this could lead to
If it works, this could offer a new treatment for unexplained recurrent miscarriage in women undergoing IVF, potentially improving live birth rates.
What could go wrong
This is a mid-stage trial with 150 participants, so results may not be definitive. G-CSF can cause side effects like bone pain and allergic reactions, and the treatment may not improve pregnancy outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MISCARRIAGES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Abortion, Spontaneous habitual spontaneous abortion pregnancy loss, recurrent, 4 pregnancy loss, recurrent, susceptibility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MISCARRIAGES RECURRENT PREGNANCY LOSS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fakih IVF Fertility Centre LLC

    RECRUITING

    Abu Dhabi, United Arab Emirates

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.